My laboratory has utilized Drosophila to address specific aspects of epithelial development and disease with a recent focus on cancer and diabetes. Our emphasis has been on in situ exploration of cellular phenomenon. To this end, we have developed several approaches including live visualization, cell ablation, computational modeling, and high throughput drug screening protocols. My laboratory's collaboration with clinicians and AstraZeneca helped bring Vandetanib to market for Medullary Thyroid Carcinoma. Our cancer genetic models are established based directly on human sequencing data and emphasize genetic complexity: we have developed multi-hit cancer models for breast, lung, and colorectal tumors. We have utilized these models to develop systems approaches towards understanding and addressing cancer metastasis and cancer metabolism. Through this work we have developed novel models for metastasis and for cancer metabolism. In addition, we have performed genetic and drug screens that have resulted in novel genes and drugs, and we are working to bring these compounds to the clinics. Working closely with medicinal chemists including Kevan Shokat, we have combined genetics and chemistry in a unique approach to developing polypharmacological agents as well as improving clinically relevant compounds. Regarding diabetes, we have established a Type 2 diabetes mellitus (T2DM) model. We are exploring the links between T2DM and obesity, hyperglycemia, hyperinsulinemia, hyperlipidemia, cardiomyopathy, and nephropathy. In collaboration with Thomas Baranski we have developed novel models for the link between obesity and diabetes and for loss of podocyte function in diabetic nephropathy. In addition, we are completing a collaboration with Francis Collins and colleagues that utilizes Drosophila as a tool for exploring GWAS studies; we have used this approach to identify novel loci linked to heightened risk for diabetes. Autism spectrum disorders (ASD) are prevalent developmental disorders, diagnosed in approximately 1% of children. Hemizygosity of the human 16p11.2 interval, a region containing 25 genes, is highly associated with ASD. This finding implies that within this interval, one (or more) gene acts as a dosage sensor, and, when present in one copy, is associated with development of ASD. We are using the zebrafish to dissect the activity and dosage sensitivity of 16p11.2 homologs during brain development. Since zebrafish do not display the complex human behaviors associated with autism, this system is not a direct phenotypic model of the human disorder. Rather, we define the fish as a "tool" which allows insight into gene function and associated pathways, by using rapid assays and screens for chemicals which modulate gene function that are not possible in mammalian systems (Sive, Dis Model Mech 4:137-8 (2011)). We identified zebrafish homologs for 20/25 genes in the 16p11.2 region, and assayed their function using a grid of eleven phenotypic assays. Our data show that this region is very active, such that 19/20 genes tested in loss of function assays give abnormal phenotypes, altering brain morphology, axon outgrowth, touch response, movement and somite or tail morphology. To date, 16 have been rescued by human mRNA expression, confirming orthology of human and fish genes. Quantitative RNA analyses have identified the AldolaseA gene as a potential hemizygosity sensor, since a decrease of 50% in RNA levels gives a strong brain phenotype. These data demonstrate that most genes within the 16p11.2 region are active during brain development, and may include a pivotal sensor for gene copy number associated with autism. Type 2 Diabetes (T2D) is a prevalent metabolic disorder associated with pancreatic ß-cell failure and complex polygenic etiologies. Genome wide association studies (GWAS) have implicated many genes, including HNF1B and WNT2B in T2D susceptibility. Further, heterozygous mutations in HNF1B can cause a form of monogenic diabetes called Maturity Onset Diabetes of the Young 5 (MODY5). The roles of these genes in pancreas development and diabetes remain elusive. We report a novel hypomorphic hnf1b mutation in zebrafish that causes MODY5-like phenotypes, islet disorganization and variable pancreas agenesis/hypoplasia, revealing that hnf1b plays a essential role in pancreas specification and morphogenesis, distinct from its function in endoderm regionalization and liver specification. Using this allele, we uncover a critical role for hnf1b in regulating ß-cell numbers and find that hnf1b/wnt2bb double mutants are synthetic lethal and exhibit a specific loss of hepatopancreatic progenitors. Our data supports a model whereby hnf1b functions to generate a permissive domain in the foregut endoderm for Wnt signaling to induce expression of T2D genes, hhex and prox1, and hepatopancreatic fate. Collectively, our findings provide a new model for MODY5, yield insight into the etiology of HNF1B diabetes, suggest a new mechanism for hepatopancreatic specification, and establish genetic interactions among genes associated with T2D. 
